Federated Hermes
BLPH

Federated Hermes’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Federated Hermes’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-153
Closed -$1K – 2364
2022
Q1 		$1K Sell
153
-11
-7% -$26 ﹤0.01% 2162
2021
Q4 		$1K Buy
+164
New +$545 ﹤0.01% 2190

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Federated Hermes's BLPH Position: Q2 2022 in Review

Federated Hermes sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2022, closing a stake of 153 shares — an estimated $1K sold.

Federated Hermes first reported a position in BLPH in Q4 2021 and held it in 2 quarters. The position peaked at $1K in Q1 2022. 19 funds tracked by Wall St. Rank hold BLPH as of Q2 2022.

  • Federated Hermes reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
  • Federated Hermes sold 153 Bellerophon Therapeutics, Inc. shares in Q2 2022, an estimated $1K.
  • Federated Hermes first reported a position in Bellerophon Therapeutics, Inc. in Q4 2021 and held it in 2 quarters.
  • Federated Hermes's Bellerophon Therapeutics, Inc. position peaked at $1K in Q1 2022.
  • 19 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.